JP2024105648A5 - - Google Patents

Info

Publication number

JP2024105648A5

JP2024105648A5 JP2024081730A JP2024081730A JP2024105648A5 JP 2024105648 A5 JP2024105648 A5 JP 2024105648A5 JP 2024081730 A JP2024081730 A JP 2024081730A JP 2024081730 A JP2024081730 A JP 2024081730A JP 2024105648 A5 JP2024105648 A5 JP 2024105648A5

Authority

JP

Japan

Prior art keywords

seq

cmklr1

compound

amino acid

set forth

Prior art date

2024-05-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Revoked

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 claims description 8
• 150000001875 compounds Chemical class 0.000 claims 51
• 102100031011 Chemerin-like receptor 1 Human genes 0.000 claims 22
• 101000919756 Homo sapiens Chemerin-like receptor 1 Proteins 0.000 claims 22
• 125000003275 alpha amino acid group Chemical group 0.000 claims 20
• 102000039446 nucleic acids Human genes 0.000 claims 17
• 108020004707 nucleic acids Proteins 0.000 claims 17
• 150000007523 nucleic acids Chemical class 0.000 claims 17
• 239000008194 pharmaceutical composition Substances 0.000 claims 17
• 239000000556 agonist Substances 0.000 claims 15
• 210000004027 cell Anatomy 0.000 claims 9
• 239000013598 vector Substances 0.000 claims 9
• 102000004127 Cytokines Human genes 0.000 claims 8
• 108090000695 Cytokines Proteins 0.000 claims 8
• 125000000539 amino acid group Chemical group 0.000 claims 6
• 230000003110 anti-inflammatory effect Effects 0.000 claims 6
• 201000011510 cancer Diseases 0.000 claims 6
• 210000000066 myeloid cell Anatomy 0.000 claims 6
• 230000026731 phosphorylation Effects 0.000 claims 6
• 238000006366 phosphorylation reaction Methods 0.000 claims 6
• 108090000765 processed proteins & peptides Proteins 0.000 claims 6
• 230000028327 secretion Effects 0.000 claims 6
• 206010009887 colitis Diseases 0.000 claims 5
• 238000000338 in vitro Methods 0.000 claims 5
• 238000001727 in vivo Methods 0.000 claims 5
• 229920001184 polypeptide Polymers 0.000 claims 5
• 102000004196 processed proteins & peptides Human genes 0.000 claims 5
• 239000000427 antigen Substances 0.000 claims 4
• 102000036639 antigens Human genes 0.000 claims 4
• 108091007433 antigens Proteins 0.000 claims 4
• 210000002540 macrophage Anatomy 0.000 claims 4
• 230000000770 proinflammatory effect Effects 0.000 claims 4
• 206010061218 Inflammation Diseases 0.000 claims 3
• 230000004913 activation Effects 0.000 claims 3
• 230000003111 delayed effect Effects 0.000 claims 3
• 208000027866 inflammatory disease Diseases 0.000 claims 3
• 230000004054 inflammatory process Effects 0.000 claims 3
• 230000002265 prevention Effects 0.000 claims 3
• 208000023275 Autoimmune disease Diseases 0.000 claims 2
• 201000009030 Carcinoma Diseases 0.000 claims 2
• 208000035473 Communicable disease Diseases 0.000 claims 2
• 208000011231 Crohn disease Diseases 0.000 claims 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
• 102000003814 Interleukin-10 Human genes 0.000 claims 2
• 108090000174 Interleukin-10 Proteins 0.000 claims 2
• 102000013462 Interleukin-12 Human genes 0.000 claims 2
• 108010065805 Interleukin-12 Proteins 0.000 claims 2
• 206010024291 Leukaemias acute myeloid Diseases 0.000 claims 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
• 102100033914 Retinoic acid receptor responder protein 2 Human genes 0.000 claims 2
• 101710170513 Retinoic acid receptor responder protein 2 Proteins 0.000 claims 2
• 239000003795 chemical substances by application Substances 0.000 claims 2
• 210000004443 dendritic cell Anatomy 0.000 claims 2
• 239000012634 fragment Substances 0.000 claims 2
• 208000015181 infectious disease Diseases 0.000 claims 2
• 201000005202 lung cancer Diseases 0.000 claims 2
• 208000020816 lung neoplasm Diseases 0.000 claims 2
• 210000004962 mammalian cell Anatomy 0.000 claims 2
• 230000010287 polarization Effects 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 206010006187 Breast cancer Diseases 0.000 claims 1
• 208000026310 Breast neoplasm Diseases 0.000 claims 1
• 208000015943 Coeliac disease Diseases 0.000 claims 1
• 206010009900 Colitis ulcerative Diseases 0.000 claims 1
• 206010009944 Colon cancer Diseases 0.000 claims 1
• 241000699802 Cricetulus griseus Species 0.000 claims 1
• 201000004624 Dermatitis Diseases 0.000 claims 1
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
• 206010013774 Dry eye Diseases 0.000 claims 1
• 201000004681 Psoriasis Diseases 0.000 claims 1
• 206010040047 Sepsis Diseases 0.000 claims 1
• 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
• 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
• 206010047115 Vasculitis Diseases 0.000 claims 1
• 230000001154 acute effect Effects 0.000 claims 1
• 230000001270 agonistic effect Effects 0.000 claims 1
• 210000004507 artificial chromosome Anatomy 0.000 claims 1
• 208000006673 asthma Diseases 0.000 claims 1
• 208000010668 atopic eczema Diseases 0.000 claims 1
• 230000020411 cell activation Effects 0.000 claims 1
• 230000004663 cell proliferation Effects 0.000 claims 1
• 208000037976 chronic inflammation Diseases 0.000 claims 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
• 208000029742 colonic neoplasm Diseases 0.000 claims 1
• 239000003246 corticosteroid Substances 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 208000030533 eye disease Diseases 0.000 claims 1
• 201000005787 hematologic cancer Diseases 0.000 claims 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
• 230000001506 immunosuppresive effect Effects 0.000 claims 1
• 206010023332 keratitis Diseases 0.000 claims 1
• 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
• 239000003446 ligand Substances 0.000 claims 1
• 206010025135 lupus erythematosus Diseases 0.000 claims 1
• 208000037819 metastatic cancer Diseases 0.000 claims 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
• 201000006417 multiple sclerosis Diseases 0.000 claims 1
• 206010028417 myasthenia gravis Diseases 0.000 claims 1
• 208000025113 myeloid leukemia Diseases 0.000 claims 1
• 208000015122 neurodegenerative disease Diseases 0.000 claims 1
• 210000001672 ovary Anatomy 0.000 claims 1
• 208000028169 periodontal disease Diseases 0.000 claims 1
• 206010034674 peritonitis Diseases 0.000 claims 1
• 239000013612 plasmid Substances 0.000 claims 1
• 230000035755 proliferation Effects 0.000 claims 1
• 230000001105 regulatory effect Effects 0.000 claims 1
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
• 239000007787 solid Substances 0.000 claims 1
• 230000002269 spontaneous effect Effects 0.000 claims 1
• 230000035897 transcription Effects 0.000 claims 1
• 238000013518 transcription Methods 0.000 claims 1
• 239000013603 viral vector Substances 0.000 claims 1
• 230000029663 wound healing Effects 0.000 claims 1
• 241001465754 Metazoa Species 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 2
• RSMZEHCMIOKNMW-GSSVUCPTSA-N Asp-Thr-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RSMZEHCMIOKNMW-GSSVUCPTSA-N 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1